Literature DB >> 8382283

Presynaptic cholinergic actions by the putative cognitive enhancing agent DuP 996.

T W Vickroy1.   

Abstract

3,3-Bis(4-pyridinylmethyl)-1-phenylindolin-2-one (DuP 996), an agent that improves the performance of rodents on memory-related behavioral tasks, was tested in rat hippocampal synaptosomes to evaluate putative direct central nervous system cholinoregulatory actions. At low micromolar concentrations, DuP 996 enhanced stimulated [3H]acetylcholine ([3H]ACh) release in a manner that was markedly dependent upon experimental test conditions. For tissues exposed to potassium-enriched buffer (9.4-40 mM KCl) or calcium-enriched buffer (for calcium-naive synaptosomes), DuP 996 facilitated [3H]ACh release (EC50 = 0.5 microM) only when extracellular potassium was moderately elevated (15-22.5 mM); at lower or higher potassium concentrations, DuP 996 failed to influence calcium-dependent transmitter release. However, under conditions where DuP 996 was maximally effective, there was no apparent change in presynaptic inhibition mediated through muscarinic autoreceptors. In contrast, when synaptosomes were depolarized before drug infusion (S2/S1 paradigm), the facilitatory action of DuP 996 was approximately 10-fold less potent and exhibited no dependence on extracellular potassium concentration. Relevant to the latter observation, it was noted that brief treatment with DuP 996 produced a long-lasting activation of synaptosomal high-affinity [3H]choline uptake that was completely calcium dependent and additive with high potassium. Taken together, these results indicate that DuP 996 exerts two direct but possibly distinct actions on hippocampal cholinergic nerve endings. First, this drug facilitates stimulus-dependent release of ACh through a mechanism or site that appears to be influenced by the neuronal membrane potential. In addition, DuP 996 enhances ACh synthesis and, thereby, may help replenish releasable stores of transmitter and maintain synaptic transmission during periods of intense (repetitive) neuronal firing.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382283

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Disruption of the ether-a-go-go K+ channel gene BEC1/KCNH3 enhances cognitive function.

Authors:  Akira Miyake; Shinji Takahashi; Yukihiro Nakamura; Kohei Inamura; Shun-Ichiro Matsumoto; Shinobu Mochizuki; Masao Katou
Journal:  J Neurosci       Date:  2009-11-18       Impact factor: 6.167

2.  Linopirdine blocks alpha9alpha10-containing nicotinic cholinergic receptors of cochlear hair cells.

Authors:  María E Gomez-Casati; Eleonora Katz; Elisabeth Glowatzki; María I Lioudyno; Paul Fuchs; A Belén Elgoyhen
Journal:  J Assoc Res Otolaryngol       Date:  2004-06-24

3.  Effect of the putative cognitive enhancer, linopirdine (DuP 996), on quantal parameters of acetylcholine release at the frog neuromuscular junction.

Authors:  S D Provan; M D Miyamoto
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

4.  MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice.

Authors:  S Murai; H Saito; E Abe; Y Masuda; J Odashima; T Itoh
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 5.  New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels.

Authors:  Michael A Rogawski; Carl W Bazil
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

6.  Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer.

Authors:  S P Aiken; B J Lampe; P A Murphy; B S Brown
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

7.  M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals.

Authors:  Maria Martire; Pasqualina Castaldo; Monia D'Amico; Paolo Preziosi; Lucio Annunziato; Maurizio Taglialatela
Journal:  J Neurosci       Date:  2004-01-21       Impact factor: 6.167

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.